The immune response to an organ allograft involves perpetuation of T cell infiltration and activation. Advances in understanding the mechanisms of T cell activation have placed particular emphasis on the interactions between the T-cell receptor and antigen presenting cells, with little reference to the fact that in vivo activation occurs in the physical context of extracellular matrix proteins (ECM). Indeed, the possibility that ECM proteins may have a determining role in lymphocyte adhesion and tissue localization and function is now becoming more appreciated in view of growing evidence indicating that integrins and other T cell antigens bind ECM components, with some of these components exerting synergistic effects on T-cell activation. This review focuses on the importance of interactions between lymphocytes and fibronectin, a prominent ECM component, for cell migration and function in organ allograft recipients. It explores novel therapeutic approaches based on the assumption that fibroneetin represents an active element in the process of T cell activation in the immune cascade triggered by organ transplantation. Keywords: Fibronectin, Transplantation, Acute Rejection, Chronic Rejection, Tolerance Lymphocytes recirculate between blood and lymph until the trigger of signals that stimulate their adhesion to vascular endothelium or extracellular matrix (ECM) proteins (de Sousa et al., 1991; Springer, 1994) . To emigrate through vascular endothelium, lymphocytes have to acquire strong adhesion interactions to the vessel wall while resisting to continuous sheer forces (Diamond et al., 1994) . The emerging relevance of lymphocyte ECM interactions to cell adhesion, migration, and positioning within specific tissue microenvironments emphasize the role ECM proteins may play in the functioning of the immune system in both physiological and pathological conditions (de Sousa et al., 1991 
The immune response to an organ allograft involves perpetuation of T cell infiltration and activation. Advances in understanding the mechanisms of T cell activation have placed particular emphasis on the interactions between the T-cell receptor and antigen presenting cells, with little reference to the fact that in vivo activation occurs in the physical context of extracellular matrix proteins (ECM). Indeed, the possibility that ECM proteins may have a determining role in lymphocyte adhesion and tissue localization and function is now becoming more appreciated in view of growing evidence indicating that integrins and other T cell antigens bind ECM components, with some of these components exerting synergistic effects on T-cell activation. This review focuses on the importance of interactions between lymphocytes and fibronectin, a prominent ECM component, for cell migration and function in organ allograft recipients. It explores novel therapeutic approaches based on the assumption that fibroneetin represents an active element in the process of T cell activation in the immune cascade triggered by organ transplantation. Keywords: Fibronectin, Transplantation, Acute Rejection, Chronic Rejection, Tolerance Lymphocytes recirculate between blood and lymph until the trigger of signals that stimulate their adhesion to vascular endothelium or extracellular matrix (ECM) proteins (de Sousa et al., 1991; Springer, 1994) . To emigrate through vascular endothelium, lymphocytes have to acquire strong adhesion interactions to the vessel wall while resisting to continuous sheer forces (Diamond et al., 1994) . The emerging relevance of lymphocyte ECM interactions to cell adhesion, migration, and positioning within specific tissue microenvironments emphasize the role ECM proteins may play in the functioning of the immune system in both physiological and pathological conditions (de Sousa et al., 1991 (Hynes, 1986) . These repeating units contain regions or domains which interact with a number of other matrix molecules as well as cells, and mediates functions such as cell migration, matrix assembly, differentiation, and proliferation Hynes, 1986) . Structural diversity in FN arises by regulated alternative splicing of a single gene transcript in three segments termed EIIIA, EIIIB, and V in rats, and ED-A, ED-B, and IIICS respectively in humans (Tamkun et al., 1984; Kornbli-htt et al., 1985 (Schwarzbauer, 1991) . The importance of FN in cell migration and differentiation is underscored by the observation that mice made null for this ECM protein die during embryonic development (George et al., 1993; Georges-Labouesse et al., 1996) . The role of FN in lymphocyte adhesion, migration, and activation has been illustrated in several studies (Shimizu et al., 1990; Hauzenberger et al., 1994; Ybarrondo et al., 1994; Ostergaard et al., 1995; Hunter et al., 1997) . Cellular adhesion to FN is mediated by a superfamily of heterodimeric molecules, the integrins (Hynes, 1987) . Lymphocytes have been shown to interact with sequences within the type III repeats of FN primarily via two different receptors of the 11 integrin family, the c4[1 and c5[1 (Guan, et al., 1990; Hemler et al., 1995) . Thus, 4 Ill integrin, interacts with the connecting segment-1 (CS-1), which is located within the V region, and with a recently described segment KLDAPT located in FN-III5 (Moyano et al., 1997 (Postigo et al., 1993), 3[1 , and v[l (Vogel, et al., 1990 Coito et al., 1994) . In our immunohistological and in situ hybridization studies of rat cardiac allografts, a markedly increased expression of FN, mostly vascular, in the early post-transplant period preceded cellular infiltration (Coito et al., 1994; Coito et al., 1997) . This initial up-regulation of vascular FN is a common step in both allo-and iso-transplants and may reflect a response to injury or ischemia that occur during the interval of about 45 minutes of cardiac engraftment (Coito et al., 1997 (Coito et al., 1997) . In addition, the simultaneous detection of FN and laminin (LN) in cardiac allografts, by laser scanning confocal microscopy, revealed a preferential accumulation of FN in the interstitial areas where infiltrating mononuclear cells (MNC) localize ( Fig. 1 C&D) (Coito et al., 1994) . Similarly, sensitized lymphocytes after adoptive transfer to test recipients localize in FN-rich areas of both cardiac transplants ( Fig 1E) and lymph nodes (Coito et al., 1994) . Moreover, treatment of rats with a neutralizing anti-TNF-serum significantly prolongs cardiac allograft survival, downregulates the local production of FN and reduces intragraft MNC infiltration (Coito et al., 1995 (Roberts et al., 1988; Ignotz et al., 1987) . Our data suggest a potential role for TNF-c in modulating macrophage appearance, and potentially FN expression, during cardiac allograft rejection (Coito et al., 1995 (Makarem et al., 1994 ).
Hence, it seems quite unlikely that the effects of relatively low dose CS peptide regimen upon the kinetics of, and local cell recruitment associated with acute graft rejection, could be attributed to the blockade of c4[ 1 VCAM-1 interactions. Supporting this notion are findings from mouse cardiac transplant models of persistent T cell infiltration in allografts despite anti-VCAM-1 mAb therapy, and transient T cell infiltrate in isografts, which are devoid of VCAM-1 expression (Orosz et al., 1993) . These strongly suggest a role for VCAM-l-independent collateral system(s) that mediate leukocyte sequestration during the course of acute graft-deteriorating rejection. It has been shown that the blockade of c4[ 1-dependent leukocyte endothelial adhesive interactions by treatment with anti-VLA-4 mAb (TA-2) was insufficient to delay acute rejection of pancreatic islets in rat recipients (Brown et al., 1993) . In contrast to the blockade of c4[1 FN interactions by CS 1 peptides, the protective effects afforded by targeting the 41 integrin by mAb alone are rather short-lived, and insignificant upon allo-Ag-driven mononuclear and endothelial cell activation leading to graft rejection in transplant recipients. However, in a more recent study, administration of CS 1 peptides to mice recipients of islet allografts not only abrogated graft rejection, but also prevented graft infiltration, suggesting a role for c4/FN interactions in leukocyte homing to the graft site (Stegall et al., 1999 ).
We have also tested the efficacy of CS-1 peptides in presensitized rat recipients in which therapy with rapamycin (RPM) abrogates rejection at 24h, but it does not prevent the ultimate cardiac allograft loss at 40-50 days . These long-term grafts show progressive development of arteriosclerosis, a hallmark of chronic rejection (Wasowska et al., 1996) . Indeed, an adjunctive course of CS-1 peptides in the early post-transplant phase resulted in the disappearance of the inflammatory and smooth muscle Cells from the arterial intimal of long-term recipients.
Unlike medium or large arteries in rats undergoing monotherapy, those foowing adjunctive CS-1 peptides had normal internal elastic laminea, and were free of neointimal thickening, confirming that CS-1 peptides successfully prevented the development of arterial chronic injury. Moreover, treatment with CS 1 peptides reduced gene transcript and product levels for T cell-and macrophage-derived cytokines and chemoattractants, which are known to contribute to the development of progressive chronic-type allograft failure. A similar finding was observed in a cholesterol-fed rabbit model in which treatment with CS-1 peptides specifically blocked vascular changes, and markedly diminished accelerated coronary arteriopathy (Wieder et al., 1993; Schmidbauer et al., 1994 
